𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clofarabine : In search of combinations for the treatment of patients with high-risk acute myeloid leukemia

✍ Scribed by Pellegrino Musto; Felicetto Ferrara

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
56 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clofarabine in the treatment of poor ris
Clofarabine in the treatment of poor risk acute myeloid leukaemia
✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ

Combination of 5-azacytidine and thalido
Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
✍ Azra Raza; Murtaza Mehdi; Muhammad Mumtaz; Fahad Ali; Steven Lascher; Naomi Gali πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to single‐agent therapy. Eventually, 30% of patients with MDS will progre

Fludarabine, cytarabine, and G-CSF (FLAG
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
✍ Montillo, Marco; Mirto, Salvatore; Petti, Maria Concetta; Latagliata, Roberto; M πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 45 KB πŸ‘ 2 views

Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer

mRNA expression of leukemia-associated a
mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
✍ Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Li Li; Anita Schmitt; Hiros πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 155 KB πŸ‘ 1 views

## Abstract Specific immunotherapies for patients with acute myeloid leukemia (AML) using leukemia‐associated antigens (LAA) as target structures might be a therapeutic option to enhance the graft‐__vs__.‐leukemia effect observed after allogeneic stem cell transplantation or to prolong a complete r